Measuring Acute Drug Demand in Humans
University of Maryland, Baltimore
75 participants
Aug 8, 2023
INTERVENTIONAL
Conditions
Summary
This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.
Eligibility
Inclusion Criteria5
- Age between 18 and 65 years old
- Meets Diagnostic and Statistical Manual-5 criteria for Opioid Use Disorder (OUD) (moderate or severe)
- Lifetime substance use history criterion \[blinded\]
- Medically cleared to take suvorexant and blinded study medications
- Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
Exclusion Criteria4
- Pregnant or breast feeding
- Seeking opioid use treatment
- Significant mental health or physical disorder that is expected to interfere with study participation as assessed by the study physicians or medical staff
- Known contraindications or allergies to suvorexant and/or the blinded study medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Double blind administration of suvorexant once per day during residential stay until discharge.
Double blind administration of placebo once per day during residential stay until discharge.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05829655